文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局部晚期宫颈癌放疗中肿瘤体积退缩的预后意义:风险分层分析

Prognostic implications of tumor volume reduction during radiotherapy in locally advanced cervical cancer: a risk-stratified analysis.
PubMed 文献 · Radiat Oncol · 2025-03-31

该回顾性队列纳入176例IIA-IVA期接受调强放疗的宫颈癌患者,用MRI测量肿瘤体积退缩(TVR)和淋巴结体积退缩(NVR)。TVR≥94%与5年OS和PFS改善显著相关;TVR的预后价值在CYFRA21-1<7.7 ng/ml患者中最明显,NVR≥94%亚组OS、PFS和LRFS显著更优。

要点

  • TVR≥94%与5年OS 82.7% vs 49.8%、PFS 82.5% vs 51.1%显著改善相关。
  • 同步放化疗亚组中TVR越高预后越好,单纯放疗组TVR增高未显著影响OS。
  • NVR≥94%亚组OS、PFS、LRFS显著优于NVR<94%组,DMFS仅呈改善趋势。

核心结论

  • TVR是CYFRA21-1<7.7 ng/ml且接受同步放化疗的局部晚期宫颈癌患者的关键预后标志物。
  • 在淋巴结转移亚组中,NVR≥94%的患者预后明显改善。

研究设计与样本

  • 回顾性分析176例IIA-IVA期宫颈癌患者,2012年1月至2020年12月接受调强放疗。
  • 采用三维MRI测量TVR和NVR,用Kaplan-Meier法评估OS、PFS、LRFS和DMFS,并用Cox比例风险模型分析预后因素。

主要发现

  • TVR≥94%组5年OS为82.7%,TVR<94%组为49.8%(p<0.001)。
  • TVR≥94%组5年PFS为82.5%,TVR<94%组为51.1%(p<0.001)。
  • TVR≥94%组LRFS和DMFS均优于TVR<94%组(p<0.001和p=0.012)。
  • 同步放化疗亚组中TVR越高预后越好,单纯放疗组TVR增高未显著影响OS。
  • NVR≥94%亚组OS、PFS、LRFS显著优于NVR<94%组(p<0.01),DMFS呈改善趋势(p=0.138)。

关键数值与推荐

  • TVR阈值94%:TVR≥94%与5年OS 82.7% vs 49.8%(p<0.001)及PFS 82.5% vs 51.1%(p<0.001)显著相关。
  • NVR阈值94%:NVR≥94%亚组OS、PFS、LRFS显著优于NVR<94%组(p<0.01),DMFS p=0.138。
  • CYFRA21-1阈值7.7 ng/ml:TVR的预后价值在CYFRA21-1<7.7 ng/ml患者中最明显。

临床怎么用

  • 对局部晚期宫颈癌根治性放疗患者,可用MRI测量的TVR和NVR进行风险分层。
  • TVR≥94%与更好的OS、PFS、LRFS和DMFS相关,尤其在CYFRA21-1<7.7 ng/ml且接受同步放化疗的患者中。
  • NVR≥94%与淋巴结转移亚组更好的OS、PFS和LRFS相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to identify key risk factors in locally advanced cervical cancer (LACC) patients receiving radical radiotherapy and to evaluate the prognostic significance of MRI-determined tumor volume regression (TVR) among varying risk groups. METHODS: We retrospectively analyzed a cohort of 176 cervical cancer patients (stages IIA-IVA) treated with intensity-modulated radiotherapy from January 2012 to December 2020. Three-dimensional MRI scans were utilized to measure TVR and lymph node volume regression (NVR). Kaplan-Meier analysis was employed to assess overall survival (OS), progression-free survival (PFS), local relapse-free survival (LRFS), and distant metastasis-free survival (DMFS). Prognostic factors were further analyzed using Cox proportional hazards models. RESULTS: A tumor TVR of ≥ 94% was significantly associated with improved 5-year overall survival (OS; 82.7% vs. 49.8%, p < 0.001) and progression-free survival (PFS; 82.5% vs. 51.1%, p < 0.001). Patients with TVR ≥ 94% also demonstrated superior LRFS and DMFS compared to those with TVR < 94% (p < 0.001 and p = 0.012, respectively). In the concurrent chemoradiotherapy (CCRT) subgroup, higher TVR correlated with better prognosis, whereas in patients receiving radiotherapy alone, an increased TVR did not significantly impact OS. Notably, the prognostic value of TVR was most evident in patients with CYFRA21-1 levels below 7.7 ng/ml. In the NVR ≥ 94% subgroup, OS, PFS, and LRFS were significantly better than in patients with NVR < 94% (p < 0.01), with a trend towards improved DMFS observed (p = 0.138). CONCLUSION: TVR serves as a pivotal prognostic marker in LACC patients with CYFRA21-1 levels below 7.7 ng/ml undergoing CCRT. Additionally, within the lymph node metastasis subgroup, patients achieving a NVR of ≥ 94% demonstrated a notably improved prognosis.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lin C, Xiao N, Chen Q, et al. Prognostic implications of tumor volume reduction during radiotherapy in locally advanced cervical cancer: a risk-stratified analysis. Radiat Oncol. 2025. PMID: 40165203. doi:10.1186/s13014-025-02623-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。